Pliant Therapeutics, Inc. PLRX
At closeNov 5, 2026, 4:00 PM EST
After hours · Nov 5, 4:00 PM ET
- YTD
- -33.13%
- 1 year
- -50.26%
- Market cap
- 50.52M
- EPS (ttm)
- -1.44
- Shares out
- 60.85M
- Forward P/E
- -3.32
- YTD return
- -33.13%
- 1-year return
- -50.26%
- Volume
- 340.32K
- Avg volume
- 399.45K
- Open
- 0.85
- Previous close
- 0.8518
- Day's range
- 0.7951 – 0.85
- 52-week range
- 0.8158 – 1.80
- Beta
- 1.09
- Price target
- 40.18 (+4825.4%)
- Earnings date
- Aug 7, 2024
2Y -14.8842 (-94.80%)
Key statistics
- Enterprise value
- 459.58M
- PEG ratio
- 0.00
- Price / book
- 2.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -84.08M
- Total cash
- 404.51M
- Total debt
- 60.21M
- Return on equity
- -47.52%
- Short % of float
- 12.16%
- 50-day average
- 14.08
- 200-day average
- 13.14
Analyst view
- Target (low)
- 32.00
- Target (mean)
- 40.18
- Target (high)
- 47.00
- Strong buy5
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.97688.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.99 | -0.95 | +0.04 | +4.04% |
| Aug 7, 2024 | Jun 1, 2024 | -0.85 | -0.92 | -0.07 | -8.24% |
| Aug 7, 2024 | Jun 1, 2024 | -0.85 | — | — | — |
| May 6, 2024 | Mar 1, 2024 | -0.76 | -0.78 | -0.02 | -2.63% |
| May 6, 2024 | Mar 1, 2024 | -0.76 | — | — | — |
| Feb 27, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 8, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Aug 8, 2024 | Oppenheimer | main | Outperform | Outperform |
| Aug 8, 2024 | Needham | reit | Buy | Buy |
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pliantrx.com
News
Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer 
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA) 
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer 
Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX) 
Connor Clark & Lunn Investment Management Ltd. Makes New $611,000 Investment in Pliant Therapeutics, Inc. $PLRX 
Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors 
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors 
Pliant Therapeutics Q2 EPS $(0.36) Misses $(0.34) Estimate 
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Your note
Sign in to keep a note on PLRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHEUNG LILY | Officer | Stock Award(Grant) | Jan 22, 2024 | 26,795 |
| COULIE BERNARD J | Chief Executive Officer | Sale | Jul 9, 2024 | 892,253 |
| CUMMINGS KEITH LAMONT | Chief Financial Officer | Sale | Jul 9, 2024 | 282,115 |
| HULL JOHANNES P. | Officer | Sale | Jul 9, 2024 | 259,285 |
| LEFEBVRE ERIC | Officer | Sale | Jul 9, 2024 | 213,052 |
| OUIMETTE MICHAEL | General Counsel | Sale | Jul 9, 2024 | 94,044 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 9.81% | 5,972,257 | 79.67M | Sep 29, 2024 |
| Blackrock Inc. | 8.58% | 5,218,965 | 69.62M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 7.94% | 4,834,813 | 64.50M | Sep 29, 2024 |
| FMR, LLC | 6.41% | 3,899,481 | 52.02M | Sep 29, 2024 |
| Vanguard Group Inc | 5.80% | 3,526,514 | 47.04M | Sep 29, 2024 |
| Redmile Group, LLC | 5.25% | 3,197,491 | 42.65M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 3.97% | 2,414,413 | 32.21M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.34% | 2,030,496 | 27.09M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.40% | 1,462,592 | 19.51M | Oct 30, 2024 |
| Fidelity Growth Company Fund | 2.18% | 1,324,096 | 17.66M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.44% | 873,606 | 11.65M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.95% | 579,914 | 7.74M | Aug 30, 2024 |